FREELINE Trademark

Trademark Overview


On Friday, November 23, 2018, a trademark application was filed for FREELINE with the United States Patent and Trademark Office. The USPTO has given the FREELINE trademark a serial number of 79255127. The federal status of this trademark filing is REGISTERED as of Tuesday, March 3, 2020. This trademark is owned by Freeline Therapeutics Limited. The FREELINE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorde...
freeline

General Information


Serial Number79255127
Word MarkFREELINE
Filing DateFriday, November 23, 2018
Status700 - REGISTERED
Status DateTuesday, March 3, 2020
Registration Number5999142
Registration DateTuesday, March 3, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 17, 2019

Trademark Statements


Goods and ServicesPharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
Pseudo MarkFREE LINE

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 27, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameFreeline Therapeutics Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameFreeline Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameFreeline Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Monday, February 6, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, August 15, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, July 24, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, July 8, 2020FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, July 8, 2020FINAL DISPOSITION PROCESSED
Wednesday, June 3, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, March 3, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, December 17, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 17, 2019PUBLISHED FOR OPPOSITION
Wednesday, November 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 12, 2019ASSIGNED TO LIE
Thursday, November 7, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 6, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 6, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 6, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 14, 2019REFUSAL PROCESSED BY IB
Wednesday, May 8, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, May 7, 2019REFUSAL PROCESSED BY MPU
Wednesday, April 17, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, April 16, 2019NON-FINAL ACTION WRITTEN
Tuesday, April 2, 2019APPLICATION FILING RECEIPT MAILED
Wednesday, March 27, 2019ASSIGNED TO EXAMINER
Wednesday, March 27, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 25, 2019LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, March 21, 2019SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB